NCT07711548Not yet recruiting
Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?
DIETary Strategies to stabiLize Incretin-based Weight Loss in Obesity Management
Source: ClinicalTrials.gov · Last updated 20 Jul 2026
Brief summary (registry, in English)
So far, treatment with semaglutide (Wegovy) for therapy of obesity demonstrates substantial effects. However, most patients do not desire life-long pharmaceutical therapy or discontinue this treatment regime. This is accompanied by rapid weight regain. Moreover, numerous patients are open to an intermittent therapy. This trial aims to investigate whether two diet interventions can keep weight stable after weight loss with semaglutide in people with obesity or overweight.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 292 (estimated)
- First submitted
- 14 Jul 2026
- Start date
- Mar 2027
- Primary completion date
- Feb 2030
- Lead sponsor
- Knut Mai
- Diseases
- Obesity
- NCT number
- NCT07711548
What you commit to
- Study type: Interventional
- Planned participants: 292
- From Mar 2027 to the primary completion date, Feb 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- concurrent pregnancy and breastfeeding
Other illness
- uncontrolled hypertension
- severe hepatic or renal diseases
- severe food allergy or malabsorption disease
- active cancer
- condition after bariatric surgery
- history of eating disorder
Lab values
- intake of glucose lowering drugs
Other
- BMI ≥ 45 kg/m²
- presence of incretin-based treatment
- acute severe CVD
Who the study is looking for
- BMI ≥ 30 kg/m² OR ≥ 27 kg/m² with concomitant cardiometabolic risk factors (metabolic syndrome, elevated blood pressure, dyslipidemia or impaired glucose metabolism (but not type 2 diabetes)
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.